Primary open-angle glaucoma is characterized by the progressive
degeneration of the optic nerve, with the high intraocular pressure
(IOP) being one of the main risk factors. The human trabecular meshwork
(HTM), specifically the juxtacanalicular tissue (JCT), is responsible
for placing resistance to the aqueous humor (AH) outflow and the resulting
IOP control. Currently, the lack of a proper in vitro JCT model and the complexity of three-dimensional models impede
advances in understanding the relationship between AH outflow and
HTM degeneration. Therefore, we design an in vitro JCT model using a polycaprolactone (PCL) nanofibrous scaffold, which
supports cells to recapitulate the functional JCT morphology and allow
the study of outflow physiology. Mechanical and morphological characterizations
of the electrospun membranes were performed, and human trabecular
meshwork cells were seeded over the scaffolds. The engineered JCT
was characterized by scanning electron microscopy, quantitative real-time
polymerase chain reaction, and immunochemistry assays staining HTM
cell markers and proteins. A pressure-sensitive perfusion system was
constructed and used for the investigation of the outflow facility
of the polymeric scaffold treated with dexamethasone (a glucocorticoid)
and netarsudil (a novel IOP lowering the rho inhibitor). Cells in
the in vitro model exhibited an HTM-like morphology,
expression of myocilin, fibronectin, and collagen IV, genetic expression,
outflow characteristics, and drug responsiveness. Altogether, the
present work develops an in vitro JCT model to better
understand HTM cell biology and the relationship between the AH outflow
and the HTM and allow further drug screening of pharmacological agents
that affect the trabecular outflow facility.